Work

C-105 Clinical trial of HER2 cancer vaccine shows benefit in 45% of evaluable patients in phase I study

Year: 2019

Type: conference-abstract

Source: JAIDS Journal of Acquired Immune Deficiency Syndromes

DOI: 10.1097/01.qai.0000557959.74614.41

Authors: Jay Berzofsky, Lauren Wood, Hoyoung Maeng, Jane Trepel, David Stroncek, John Morris

Institutions: National Institutes of Health, National Cancer Institute, National Institutes of Health Clinical Center, University of Cincinnati, University of Cincinnati Medical Center

Language: English

Topic: Immunotherapy and Immune Responses

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2938044882

Cites:

Cited by:

Related to: 10